Abstract
BackgroundL-Arabinose is a non-caloric sugar, which could affect glucose and lipid metabolism and suppress obesity. However, few reports have described the effect of L-arabinose in metabolic syndrome, a combination of medical disorders that increase the risk of diabetes and cardiovascular disease.ObjectiveThis study was conducted to explore the effects of L-arabinose in rats with metabolic syndrome induced by a high-carbohydrate, high-fat (HCHF) diet.MethodsAfter the rat model for metabolic syndrome was successfully established, L-arabinose was administrated by oral gavage for 6 weeks. The biochemical index and histological analysis were measured, and the expression levels of genes related to fatty acid metabolism were analyzed using real-time PCR.ResultsFollowing treatment with L-arabinose, metabolic syndrome rats had an obvious reduction in body weight, systolic blood pressure, diastolic blood pressure, fasting blood glucose, triglycerides, total cholesterol, serum insulin, TNF-α, and leptin. Further study showed that treatment with L-arabinose significantly increased the expression of mRNA for hepatic CPT-1α and PDK4, but the expression of mRNA for hepatic ACCα was reduced.ConclusionsThis work suggests that L-arabinose could lower body weight, Lee's index, and visceral index and improve dyslipidemia, insulin resistance, inflammation, and viscera function, which indicate that it might be a promising candidate for therapies combating metabolic syndrome.
Highlights
L-Arabinose is a non-caloric sugar, which could affect glucose and lipid metabolism and suppress obesity
Rats in the metabolic syndrome group had heavier body weight and higher diastolic blood pressure (DBP) and systolic blood pressure (SBP) compared to the control group
Animals exhibited a significant increase in fasting blood glucose (FBG) and fasting insulin (FINS); in addition, lipid metabolism disorders were manifested as fatty and hyperlipidemia (Table 2)
Summary
L-Arabinose is a non-caloric sugar, which could affect glucose and lipid metabolism and suppress obesity. Few reports have described the effect of L-arabinose in metabolic syndrome, a combination of medical disorders that increase the risk of diabetes and cardiovascular disease. Objective: This study was conducted to explore the effects of L-arabinose in rats with metabolic syndrome induced by a high-carbohydrate, high-fat (HCHF) diet. Methods: After the rat model for metabolic syndrome was successfully established, L-arabinose was administrated by oral gavage for 6 weeks. Results: Following treatment with L-arabinose, metabolic syndrome rats had an obvious reduction in body weight, systolic blood pressure, diastolic blood pressure, fasting blood glucose, triglycerides, total cholesterol, serum insulin, TNF-a, and leptin. Conclusions: This work suggests that L-arabinose could lower body weight, Lee’s index, and visceral index and improve dyslipidemia, insulin resistance, inflammation, and viscera function, which indicate that it might be a promising candidate for therapies combating metabolic syndrome
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
